Do weight loss injections help get rid of snoring and sleep apnea?

These results raise an important question: Could weight loss injections become part of the treatment for sleep apnea, and perhaps help some patients reduce their reliance on breathing devices?

The two studies included people suffering from moderate to severe obstructive sleep apnea, along with being overweight or obese, including patients with type 2 diabetes.

According to the figures provided in the trial results, the average number of breathing disorder episodes in one study decreased by about 34 episodes per hour in the group that received a 9-milligram dose, compared to about 10 episodes in the placebo group.

In the other study, the decrease in the treatment groups ranged between about 25 and 25.4 episodes per hour, compared to about 10 episodes in the placebo group.

Participants also recorded a significant decrease in their weight, which reinforces the possibility that weight loss is one of the main factors behind the improvement in sleep breathing.

However, these results do not necessarily mean the disorder disappears in all patients, nor do they prove that the drug treats all its causes.

Obstructive sleep apnea occurs when the upper airways narrow or close repeatedly during sleep as a result of the relaxation of the surrounding muscles.

This can lead to temporary cessation of breathing, a drop in blood oxygen levels, and frequent short awakenings that affect sleep quality, even if the person is unaware of them.

Loud snoring is considered a common sign, especially when accompanied by choking during sleep or if a family member notices breathing pauses, in addition to morning headaches and daytime sleepiness.

Obesity increases the risk of the condition due to the accumulation of fat around the neck, tongue, and tissues surrounding the airway, making obstruction more likely.

However, snoring does not necessarily mean there is a breathing pause, and this disorder can also affect people who are not overweight.

Retatrutide works on three hormonal receptors associated with appetite and metabolism regulation: GLP-1, GIP, and glucagon.

By helping to reduce weight, this class of treatments may contribute to reducing the fat surrounding the airway, allowing for better airflow during sleep.

But it remains important to distinguish between treating obesity and improving sleep apnea itself; it cannot be assumed that weight loss will eliminate the disorder for everyone, or that the drug has an effect independent of weight loss without additional evidence.

The Continuous Positive Airway Pressure (CPAP) device is one of the widely used treatments for obstructive sleep apnea, as it keeps the airway open during the night.

Despite its effectiveness, some patients find it difficult to adapt to the mask or commit to using it regularly.

Weight loss medications may represent an additional option for some people with obesity, but they are not considered an automatic alternative to the device, and prescribed treatment should not be stopped without consulting a doctor.

Also, retatrutide is still an experimental drug and cannot be considered an approved treatment for this condition. Its side effects may include digestive disorders, in addition to other risks that require medical evaluation.

Not every snore is a sign of a serious illness, but loud snoring accompanied by breathing pauses or a feeling of choking during sleep requires medical evaluation.

Untreated sleep apnea may be linked to high blood pressure, heart problems, poor concentration, and drowsiness while driving.

A doctor may recommend a sleep study to determine the severity of the disorder and choose the appropriate treatment, whether it is a breathing device, weight loss measures, or other options depending on the case.

Conclusion: Weight loss may help improve obstructive sleep apnea in some people with obesity, but weight loss injections are not a comprehensive solution for snoring and do not necessarily replace breathing devices. As for retatrutide, it still needs further scientific and regulatory evaluation before it can be considered a treatment option available for general use.